Organization will evaluate the effectiveness of firm’s proprietary resolvins.
National Neurovision Research Institute (NNRI) and Resolvyx Pharmaceuticals inked a research collaboration whereby NNRI will fully fund preclinical studies to evaluate the potential of resolvin therapeutics for eye diseases of the retina that lack current treatments, specifically genetic retinal degenerative diseases and dry age-related macular degeneration (AMD).
NNRI will fully fund preclinical studies and will also provide access to specialized research facilities and ocular research experts to conduct studies to evaluate the effectiveness of resolvins for specific eye diseases. Resolvyx will provide the company’s resolvin therapeutics, including RX-10001, RX-10008, and RX-20001, for the research studies. Resolvyx will retain all rights to develop and commercialize these compounds and any discoveries that result from the collaboration.
Resolvins are a recently discovered family of naturally occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases, according to Resolvyx. In particular, resolvins act to protect healthy tissue during an immune response to infection, injury, or other environmental challenge, prevent cell death, and then act to resolve inflammation and promote healing after the insult has passed.
